Page 180 - 2021_05-Haematologica-web

O. Moser et al.
Late health outcomes after contemporary
lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2019;37(28):2556-2570.
12. Ehrhardt MJ, Sandlund JT, Zhang N, et al. Late outcomes of adult survivors of child- hood non-Hodgkin lymphoma: a report from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer. 2017;64(6).
13. Tward JD, Wendland MM, Shrieve DC, Szabo A, and Gaffney DK. The risk of sec- ondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107(1):108-115.
14. Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, and Sacchi S. Risk for sec- ond malignancies in non-Hodgkin’s lym- phoma survivors: a meta-analysis. Ann Oncol. 2011;2(8)2:1845-1858.
15. Lennert K, Stein H, and Kaiserling E: Cytological and functional criteria for the classification of malignant lymphoma. Br J Cancer. 1975;31(Suppl 2):29-43.
16. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lym- phoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361-1392.
17. World Health Organization Classification of Tumours 2001. Pathology and genetics of tumours of haematopoietic and lym- phoid tissues. IARC Press, Lyon.
18. Murphy SB. Classification, staging and end results of treatment in childhood non Hodgkin’s lymphoma: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332-339.
19. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate admin- istration schedule and dose in the treat- ment of children and adolescents with B- cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948- 958.
20. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma- type chemotherapy is efficacious treatment
for pediatric anaplastic large cell lym- phoma: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-3706.
21. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B- cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294-3306.
22.Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of child- hood: a prospective analysis of 62 patients enrolled in three consecutive Berlin- Frankfurt-Munster group studies. J Clin Oncol. 1994;12(5):899-908.
23. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B-cell acute lym- phoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;80(10):2471-2478.
24. Kalbfleisch J, Prentice RL. The statistical analysis of failure time data. New York, NY: John Willey. 1980;163.
25. Kaplan EL and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
26. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lympho- proliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317.
27. Leone G, Voso MT, Sica S, Morosetti, and Pagano L. Therapy related leukemias: sus- ceptibility, prevention and treatment. Leuk Lymphoma. 2001;41(3-4):255-276.
28. Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol. 2000;109(1):13-23.
29. Löning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin- Frankfurt-Münster therapy of acute lym- phoblastic leukemia in childhood: signifi- cantly lower risk without cranial radiother-
apy. Blood. 2000;95(9):2770-2775.
30. Paganin M, Buldini B, Germano G, et al. A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatr Blood Cancer.
2016;63(9):1660-1663.
31. Maule M, Scelo G, Pastore G, et al. Risk of
second malignant neoplasms after child- hood leukemia and lymphoma: an interna- tional study. J Natl Cancer Inst. 2007;99(10):790-800.
32.Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354(9172):34-39.
33. Ripperger T, Schlegelberger B. Acute lym- phoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur J Med Genet. 2016;59(3):133-142.
34. Wimmer K, Kratz CP, Vasen HF, et al. EU- Consortium Care for CMMRD (C4CMMRD). Diagnostic criteria for con- stitutional mismatch repair deficiency syn- drome: suggestions of the European con- sortium 'care for CMMRD' (C4CMMRD). J Med Genet. 2014;51(6):355-365.
35. Attarbaschi A, Carraro E, Abla O, et al. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteris- tics and outcome in 213 children and ado- lescents. Haematologica. 2016; 101(12):1581-1591.
36. Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1686-1695.
37. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol. 1994;5(Suppl 2):S29-35.
38. Ripperger T, Bielack SS, Borkhardt A, et al. Childhood cancer predisposition syn- dromes-A concise review and recommen- dations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet. 2017;173(4):1017-1037.
1400
haematologica | 2021; 106(5)